Despite the excellent clinical performance of fluorodeoxyglucose (FDG) as a cancer-imaging agent for positron emission tomography (PET), false positive and false negative results can be problematic in some clinical settings. Radiopharmaceutical development has recently focussed on the search for new PET tracers that could complement or replace FDG in such settings. Due to the general availability and favourable physical properties of fluorine-18, much effort has been directed to fluorinated compounds. The most promising of these are discussed.

Author

Rodney J Hicks

Contact Details

Corresponding address:
Centre for Molecular Imaging,
The Peter MacCallum Cancer Centre,
Melbourne,
Australia

Reference

ICIS Cancer Imaging volume 4
DOI: 10.1102/1470-7330.2003.0032

Date Posted

2 September 2003

Print PDF

Size

1.00 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	4 seconds
ADSL 512Kb/s (Broadband):	16 seconds
64 Kb/s (ISDN):	2 minutes 8 seconds
33.3 Kb/s (Typical Modem):	4 minutes 6 seconds

Screen PDF

Size

180.39 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	2 seconds
64 Kb/s (ISDN):	22 seconds
33.3 Kb/s (Typical Modem):	43 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.